Pharma BD Deal Intelligence

Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd.

2020 · Co-Development · $255M · Complete

Announcement Sentiment

Positive

Eli Lilly and Junshi Biosciences entered a co-development agreement for SARS-CoV-2 neutralizing antibodies (lead JS016, later named etesevimab) for COVID-19 prevention and treatment. Lilly paid $10M upfront with up to $245M in milestones and double-digit royalties; Lilly secured exclusive rights ex-Greater China while Junshi retained Greater China rights. Lilly also committed to a $75M conditional Junshi share subscription.

Key facts

Announced May 04, 2020
Closed May 04, 2020
Deal value $255M
Deal type Co-Development
Therapeutic area COVID-19 prevention and treatment
Indications COVID-19 prevention and treatment
Key assets JS016 (etesevimab) and other neutralizing antibodies
Mechanism SARS-CoV-2 spike protein-neutralizing monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals